Markets

News Details

( 30/07/2018 07:17)
Sun Pharma recalls over 2,500 bottles of diabetes drug from US

The US arm of Sun Pharmaceutical Industries is recalling over 2,500 bottles of Metformin hydrochloride extended release tablets from Arizona on account of presence of foreign substance in one lot, reported PTI.

United States Food and Drug Administration (USFDA) said the company is recalling 2,508 bottles of Metformin hydrochloride extended release tablets 500 mg, packaged in a 500-count bottle.

The reason for recall is presence of foreign substance- one lot of these tablets contains foreign matter identified as a piece of rubber glove detected in one tablet= it added.

The tablets were manufactured at Sun Pharma's Halol facility, USFDA said in its Enforcement report.

The ongoing, voluntary recall is a class II recall, it added.

As per USFDA, a class II recall is initiated in a situation "in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."

Metformin hydrochloride extended release tablets are used to improve glycemic control in adults with type 2 diabetes.

ATTENTION INVESTORS 1 : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case | 2 : "Prevent Unauthorized Transactions in your demat / trading account --> Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors. | 3 : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

SEBI Regn. NSE: INB231280430 I F&O: INF231280430 I BSE: INB011280436 I NSE CD: INE231280430 I MCX-SX: INE261280430

Copyright © 2017 Rikhav Securities Ltd. All rights reserved

Designed , Developed & Content Powered by DION